Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a commercial-stage biotech spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high-impact pathologies and major social burdens such as invalidating OsteoArthritis, Skin Aging and Ophthalmology. KiOmed Pharma’s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. | Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a commercial-stage biotech spinout from KitoZyme and the University of Liege, has developpeds a unique pipeline of medical devices that address unmet medical needs in high-impact pathologies and major social burdens such as invalidating OsteoArthritis, Skin Aging and Ophthalmology. KiOmed Pharma’s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. KioMedine-vs-one, the company’s first product, currently commercialized in 15 countries, is a unique fluid implant indicated for the symptomatic treatment of knee osteoarthritis via a single intraarticular injection, providing up to 12 months symptom relief. KioMedine-vs-one is targeted to refractory knee OA patients, who do not respond well to existing treatments and constitutes for these patients a cost-effective alternative to TKR surgery, that can potentially be delayed or avoided.
I+MED S.COOP.
i+Med is a biomedical engineering company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value. We are knowledge generators. A cooperative of scientists positioned as one of the world leaders in the field of nanohydrogels and controlled release. We are specialists in the development of smart nanohydrogels and controlled release of active ingredients. We apply our expertise around different technologies, supported by our 5 patents, thus customising different solutions tailored to our client’s needs. | i+Med is a biomedical engineering company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value. We are knowledge generators. A cooperative of scientists positioned as one of the world leaders in the field of controlled release systems, turnable hydrogels and nanohydrogels. We are specialists in the development of smart nanohydrogels and controlled release of active ingredients such as different APIs, peptides or bio. We apply our expertise around different technologies, supported by our patents, thus customising different solutions tailored to pharmaceutical companies needs. Our headquarters are located in Vitoria, Basque Country, in the north of Spain. In our facilities we develop an active R&D activity for third parties and manufacture high added value medical devices for traumatology, aesthetics, ophthalmology and dermatology that we distribute worldwide. We have a team of more than 150 employees focused on generating innovative biomedical solutions to cover unmet medical needs.
Eco Polymer Science & Technology Inc
ECO Polymer is a trusted extrusion partner to MedTech, Biotech, and life sciences teams. We produce a wide range of precision polymer tubing. From general grade to high-performance engineering materials, for diverse medical and technical applications. Whether you’re launching a new device or optimizing an existing one, we offer: ISO 13485-certified operations Class 7 clean room capabilities Costa Rica expansion to support nearshore manufacturing and reduce lead times Fast, flexible turnaround Custom extrusion solutions for early-stage to high-volume needs We’re more than a vendor, we’re a partner. ECO Polymer is proactive in tariff mitigation, maintaining competitive pricing, and building resilient supply chains. If you’re seeking a supplier who feels like part of your team, stop by our booth. Let’s collaborate to streamline your supply chain, accelerate time-to-market, and exceed compliance standards, without compromising quality. | Eco Polymer is a global materials engineering company specializing in advanced polymer solutions for medical devices, diagnostics, and membrane filtration. We provide medical-grade tubing, catheter components, functional coatings, and custom membrane technologies supported by in-house R&D expertise. Founded with a focus on innovation and quality, Eco Polymer is expanding its global footprint and is set to open a cleanroom facility in Costa Rica before the end of 2026. Our most recent acquisition of Suzhou Anthway Biotech, a specialist in lab-scale membrane and filtration systems, enhances our in-house operations. These strategic expansions strengthen Eco Polymer’s ability to deliver innovative solutions to customers worldwide. | Shanghai Eco Precision Extrusion Technology Company Ltd. is a medical plastic tubing manufacturer that uses various materials such as PEEK, PTFE, PPSU, PSU, PU, nylon, PEBAX, PP, PE, ABS, EVA, PETG, PVDF, and more. The company also manufactures OEM semifinished and finished products, wuch as double J stents, biliary drainage catheters, biliary plastic stents, cold snares, cytology brushes, and more.Â
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Cincinnati Children’s Innovation Ventures
Cincinnati Children’s is a nationally ranked pediatric health system and a recognized leader in both pediatric and adult research. With a legacy of impact spanning more than 90 years—from Albert Sabin’s oral polio vaccine to pioneering discoveries in lung surfactant proteins—we continue to advance science that improves lives. As one of the largest pediatric research institutions in the U.S., we secure $300 million in external research funding annually and play a central role in shaping the future of biomedical innovation. Innovation is embedded in our culture. One-third of our 19,000 employees are engaged in research and innovation across a broad spectrum of life sciences. From breakthrough therapeutic candidates and biotech platforms to diagnostics, medical devices, software, and research tools, our teams are building a pipeline of technologies with the potential for real-world impact. Explore our innovation portfolio and partnership opportunities at cincinnatichildrens.org/innovation-ventures.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
Biosima
BioSima, a biotech company founded in 2022 and based in Brazil, has pioneered an innovative platform for developing exosome-based biopharmaceuticals. BioSima’s products are focused on addressing unmet medical needs by conventional therapies applied in Endocrinology (Diabetes), bone reconstruction (Orthopedics and Dentistry), and Neurology (Alzheimer’s disease). BioSima’s biopharmaceuticals are developed utilizing cutting-edge R&D techniques applicable for regenerative medicine, employing exosome concentrates—nanometric extracellular vesicles produced naturally by living cells and concentrated through specific patented methods. Acting as active ingredients of biopharmaceuticals, these exosomes deliver their genetic and protein cargo to target local undifferentiated cells, aiming to stimulate their proliferative and differentiation potential for healing and repairing of diseased living tissues and organs. BioSima has built a solid track record in Brazil’s biotechnology innovation landscape, achieving significant financial milestones that strengthen its scientific and technological development capacity. Since its inception, the company has stood out in highly competitive public funding programs for applied research, securing support through federal initiatives in Brazil such as FINEP and the Ministry of Science, Technology and Innovation (MCTI). A key highlight is its approval under the “INOVADOC-Brazil” FINEP program, which provides non-reimbursable grants to high-impact projects in health and sustainability. In addition to government-backed funding, BioSima has successfully attracted seed capital from private sources — including angel investors with equity-based funding mechanisms tailored to deep tech startups. This financial support has enabled the company to structure a robust program for the development of exosome-based therapeutic products. It has also driven the consolidation of BioSima’s R&D infrastructure, the development of analytical methods, and the execution of preclinical safety and efficacy studies, both in vitro and in vivo. These advancements have positioned BioSima strategically to start regulatory planning and the technical processes required for clinical trial submissions to health authorities such as ANVISA (Brazil), FDA and EMA, in compliance with international good practices in biopharmaceutical development. The company’s financial and operational achievements to date reflect not only its strong technical foundation but also its institutional readiness and business maturity to meet the complex challenges of healthcare innovation.
Biopôle SA
Biopôle Lausanne is one of the largest life sciences campus in Europe, hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne, Switzerland (www.biopole.ch). It offers a world-class combination of modern infrastructure (134,000 sqm of office/lab space), added value services, an extensive network, innovation and funding programmes, and unparalleled community engagement where members can thrive and bring science to life. Biopôle houses 130+ life sciences companies, including 50 biotech/pharma such as Ferring, Roche, Ichnos, etc. and world-class research organizations (Lausanne University Hospital (CHUV), University of Lausanne (UNIL), the Ludwig Institute for Cancer Research etc.), a life science incubator (StartLab), ready-to-move-in private labs (Superlab), a Digital Health Hub (DH2) enabling the emergence of outstanding innovation for the betterment of healthcare. Join Biopôle.
BioProcess International
BioProcess International (BPI) is a global brand focused on bringing you the latest scientific innovation and technologies across the entire spectrum of biopharmaceutical development and production. BPI produces an industry-leading publication, world-renowned conferences, webinars, eBooks, online training courses, news outlets and more. Learn more about BPI at https://www.bioprocessintl.com/ | BioProcess International™ is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. BioProcess International also hosts a series of global events across Boston, California, Europe and Asia. For more information about the BPI publication and events, visit https://informaconnect.com/bioprocess-international-events/?utm_source=bio-conference&utm_medium=web-listing